As far as I can tell, Admedus is pretty unique in the Oz biotechy & microcap space.... the CEO is in a position to give us realistic guidance on profitability, plus or minus a quarter. I mean. I would have thought that's a pretty good debate to have. Not whether the company relies on a binary event (such as other companies like Resapp or Neuren) but simply whether they are gunna hit profitability on time. All the other stuff like TAVR & HPV vax development is pure bluesky that most bio companies on the ASX would love to have as their main commercial strategy....
Ann: Appendix 4C - quarterly, page-162
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.20 |
Change
-0.550(3.10%) |
Mkt cap ! $330.6M | |||
| Open | High | Low | Value | Volume |
| $17.75 | $17.75 | $16.88 | $199.1K | 11.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $17.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.24 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |